Healthcare Industry News: Alzheimer's
News Release - June 18, 2007
Gene Logic Collaboration Reveals Genomic Predictors of Parkinson's DiseaseResults Predict Likelihood and Age of Disease Onset, May Lead to Risk-Assessment Tests
GAITHERSBURG, Md.--(HSMN NewsFeed)--Gene Logic Inc. (NASDAQ:GLGC ) announced today that a collaborative study between its Genomics Division and Mayo Clinic has found biomarkers that predict susceptibility to Parkinson's disease and age of disease onset. The study was novel in its detailed and comprehensive analysis of genes and their polymorphic variants across a specific biologic pathway. This work may also provide a model for the study of other complex diseases such as Alzheimer's.
Parkinson's disease is a chronic and progressive movement disorder that affects nearly one million Americans. The collaborators used sophisticated bioinformatic analysis methods to compare gene sequence variations called single nucleotide polymorphisms (SNPs) in the genomes of Parkinson's disease patients to those of their disease-free siblings. The collaborators targeted variants of genes related to the axon guidance pathway, a neural development pathway that plays an important role in the wiring of the brain during fetal development.
Gene Logic provided gene expression data analysis and data interpretation, comparing the whole-genome study data to the company's Parkinson's disease gene expression knowledgebase, referred to in the study as the most comprehensive such database to date. Jarlath ffrench-Mullen, Ph.D., Gene Logic Scientific Director, Central Nervous System, and a co-author of the study said, "The study methodology opens doors to more in-depth genetic understanding of complex diseases, demonstrating the value of our clinical and genomics assets and capabilities. Gene expression profiles are used in such studies to identify, understand and confirm the dysregulation of specific genes and gene variants in a target pathway. This study augments our intellectual property position around a growing set of useful markers for Parkinson's disease and other complex diseases, affording excellent opportunities to develop diagnostic, prognostic, or therapeutic products."
Gene Logic Overview
Gene Logic is transforming into a biopharmaceutical development company through partnerships with pharmaceutical companies. Our partners provide Gene Logic with access to their drug candidates that have been assessed as safe in human clinical trials but discontinued for other reasons. Gene Logic applies its drug indication platform to find new therapeutic uses for the drug candidates. Gene Logic expects to receive milestone payments and royalties on drug candidates that our partners choose to develop based on the indications we find or, if the partner elects not to pursue such new indications, Gene Logic may receive ownership and development rights.
Gene Logic has also developed proprietary genomics databases and services to enable customers worldwide to discover and prioritize drug targets, identify biomarkers, predict toxicity and understand mechanisms of toxicity, and obtain insights into the efficacy of specific compounds.
Founded in 1994, Gene Logic is headquartered in Gaithersburg, Maryland, with additional research and development facilities in Cambridge, Massachusetts. The Company currently has about 150 employees worldwide. For more information, visit www.genelogic.com or call toll-free - 1/800/GENELOGIC.
Safe Harbor Statement
This press release contains "forward-looking statements," as such term is used in the Securities Exchange Act of 1934, as amended. Such forward-looking statements include the Company's ability to identify strategies for making its businesses successful and the impact of such strategies on our business and financial performance and on shareholder value. Forward-looking statements typically include the words "expect," "anticipate," "believe," "estimate," "intend," "may," "will," and similar expressions as they relate to Gene Logic or its management. Forward-looking statements are based on our current expectations and assumptions, which are subject to risks and uncertainties. They are not guarantees of our future performance or results. Our actual performance and results could differ materially from what we project in forward-looking statements for a variety of reasons and circumstances, including particularly such risks and uncertainties that may affect the Company's operations, financial condition and financial results and that are discussed in detail in the Company's Annual Report on Form 10-K and our other subsequent filings with the Securities and Exchange Commission. They include, but are not limited to: whether we will be able to identify and successfully implement strategies, on favorable terms or at all, for improving the performance and value of our businesses and improving the value of our Genomics business and whether repositioned compounds are successfully returned to our customers' pipelines and generate sales, and resulting milestones and royalties for the Company or whether we acquire repositioned compounds on acceptable terms and are able to derive revenue from these compounds through licensing or otherwise, whether we can enter into agreements to develop sufficient compounds to fulfill our plans for the Drug Repositioning Division, and improving the value of our businesses to shareholders; whether there will be remaining price adjustments or liabilities associated with the sale of the Pre-Clinical Division, whether we will be able successfully to manage our existing cash adequately and whether we will have access to financing on sufficiently favorable terms to maintain our businesses and effect our strategies, including development of repositioned compounds; whether we will be able to recruit and retain qualified personnel, particularly in light of our restructuring efforts; potential negative effects on our operations and financial results from workforce reductions, other restructuring activities, and the evaluation of strategic options; the potential loss of significant customers; the possibility of further write-down of the value of certain intangible assets of the Company, including goodwill associated with the Genomics Division; and the possibility of delisting from NASDAQ Global Markets, which could have an adverse effect on the value of our stock. Gene Logic undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Gene Logic
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.